z-logo
Premium
Distribution of human leucocyte antigen‐A, ‐B and ‐DR alleles and haplotypes at high resolution in the population from Jiangsu province of China
Author(s) -
Qin Qin P.,
Su F.,
Xiao Yan W.,
Xing Z.,
Meng P.,
Chengya W.,
Jie S.
Publication year - 2011
Publication title -
international journal of immunogenetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.41
H-Index - 47
eISSN - 1744-313X
pISSN - 1744-3121
DOI - 10.1111/j.1744-313x.2011.01029.x
Subject(s) - haplotype , allele , china , genetics , population , distribution (mathematics) , biology , antigen , gene , geography , medicine , environmental health , mathematical analysis , mathematics , archaeology
Summary The frequencies of human leucocyte antigen (HLA)‐A, ‐B and ‐DRB1 alleles and haplotypes were statistically analysed among 3238 donors from Chinese Marrow Donor Program (CMDP) Jiangsu Branch. All donors were typed using polymerase chain reaction–sequence‐based typing (PCR‐SBT) method or polymerase chain reaction–reverse sequence‐specific oligonucleotide probe (PCR‐rSSOP) method. As a result, a total of 46 A, 85 B and 51 DRB1 alleles were found in Jiangsu population. The first three frequent alleles in HLA‐A, ‐B and ‐DRB1 loci respectively were A*11:01(16.52%), A*24:02(15.10%) and A*02:01(13.02%); B*13:02(11.60%), B*46:01(8.89%) and B*58:01(7.12%); and DRB1*07:01(15.78%), DRB1*09:01(15.26%) and DRB1*15:01(9.76%). The top two frequent A‐B‐DRB1 haplotypes were A*30:01‐B*13:02‐DRB1*07:01(8.87%) and A*02:07‐B*46:01‐DRB1*09:01(2.79%); the top three A‐B haplotypes were A*33:03‐B*58:01‐DRB1*03:01(2.59%), A*30:01‐B*13:02(9.92%) and A*33:03‐B*58:01(5.48%); the top two B‐DRB1 haplotypes were B*13:02‐DRB1*07:01(10.23%) and B*46:01‐DRB1*09:01(4.61%); the top two A‐DRB1 haplotypes were A*30:01‐DRB1*07:01(8.96%) and A*33:03‐DRB1*13:02(3.95%). These findings provided useful information in the study of genetics and anthropology in Chinese Han population. It also served as a basic guide for selection of future donors in CMDP Jiangsu Branch.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here